Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Guedj

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Viral Hepatitis|August 21, 2010
A perspective on modelling hepatitis C virus infectionJ Guedj, L Rong, H Dahari, et al.
L'Encephale|August 17, 2014
[The link between aggressive behavior and depression in adolescence. A cross-sectional study conducted in the psychiatric emergency unit at the Sainte-Anne hospital]X Benarous, M J Guedj, A Braitman, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2013
Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment OutcomeT H T Nguyen, J Guedj, J Yu, et al.
Clinical Pharmacology and Therapeutics|August 29, 2014
A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic responseT H T Nguyen, F Mentré, M Levi, et al.
L'Encephale|November 14, 2006
[Therapeutics approach of adult patients with acute and chronic psychotic states: REALITE survey]F R Cousin, J P Chabannes, M J Guedj, et al.
Journal of Viral Hepatitis|June 9, 2012
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirinH Guedj, J Guedj, F Negro, et al.
L'Encephale|August 10, 2013
[Decision of emergency involuntary hospitalization: categorical or dimensional approach?]A Braitman, V Dauriac-Le Masson, F Beghelli, et al.
ESMO Open|December 26, 2021
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapyM Kerioui, S Desmée, F Mercier, et al.
Alimentary Pharmacology & Therapeutics|December 23, 2017
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitorS Fourati, J Guedj, S Chevaliez, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Viral Hepatitis|August 21, 2010
A perspective on modelling hepatitis C virus infectionJ Guedj, L Rong, H Dahari, et al.
L'Encephale|August 17, 2014
[The link between aggressive behavior and depression in adolescence. A cross-sectional study conducted in the psychiatric emergency unit at the Sainte-Anne hospital]X Benarous, M J Guedj, A Braitman, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2013
Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment OutcomeT H T Nguyen, J Guedj, J Yu, et al.
Clinical Pharmacology and Therapeutics|August 29, 2014
A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic responseT H T Nguyen, F Mentré, M Levi, et al.
L'Encephale|November 14, 2006
[Therapeutics approach of adult patients with acute and chronic psychotic states: REALITE survey]F R Cousin, J P Chabannes, M J Guedj, et al.
Journal of Viral Hepatitis|June 9, 2012
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirinH Guedj, J Guedj, F Negro, et al.
L'Encephale|August 10, 2013
[Decision of emergency involuntary hospitalization: categorical or dimensional approach?]A Braitman, V Dauriac-Le Masson, F Beghelli, et al.
ESMO Open|December 26, 2021
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapyM Kerioui, S Desmée, F Mercier, et al.
Alimentary Pharmacology & Therapeutics|December 23, 2017
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitorS Fourati, J Guedj, S Chevaliez, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Pageof 3